243 related articles for article (PubMed ID: 27755140)
1. Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.
Dawood S; Rugo HS
Curr Opin Support Palliat Care; 2016 Dec; 10(4):336-342. PubMed ID: 27755140
[TBL] [Abstract][Full Text] [Related]
2. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
3. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Wang H; Ma H; Sové RJ; Emens LA; Popel AS
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579739
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
Kwa MJ; Adams S
Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
Bertucci F; Gonçalves A
Curr Oncol Rep; 2017 Aug; 19(10):64. PubMed ID: 28799073
[TBL] [Abstract][Full Text] [Related]
6. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
Monneur A; Gonçalves A; Bertucci F
Bull Cancer; 2018 Mar; 105(3):263-274. PubMed ID: 29455872
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Kang C; Syed YY
Drugs; 2020 Apr; 80(6):601-607. PubMed ID: 32248356
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
Mavratzas A; Seitz J; Smetanay K; Schneeweiss A; Jäger D; Fremd C
Future Oncol; 2020 Jan; 16(3):4439-4453. PubMed ID: 31829043
[TBL] [Abstract][Full Text] [Related]
10. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
Zhu H; Du C; Yuan M; Fu P; He Q; Yang B; Cao J
Drug Discov Today; 2020 Sep; 25(9):1762-1771. PubMed ID: 32663441
[TBL] [Abstract][Full Text] [Related]
11. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
15. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Emens LA; Molinero L; Loi S; Rugo HS; Schneeweiss A; Diéras V; Iwata H; Barrios CH; Nechaeva M; Nguyen-Duc A; Chui SY; Husain A; Winer EP; Adams S; Schmid P
J Natl Cancer Inst; 2021 Aug; 113(8):1005-1016. PubMed ID: 33523233
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
17. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
Pérez-García J; Soberino J; Racca F; Gion M; Stradella A; Cortés J
Expert Opin Biol Ther; 2020 Sep; 20(9):981-989. PubMed ID: 32450725
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PD-L1 Pathway in Breast Cancer.
Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
[TBL] [Abstract][Full Text] [Related]
19. Sarcoidosis-like reaction in metastatic triple negative breast cancer treated by anti-PD-L1.
Lafon M; Blaye C; Kind M; Bechade D; Chassaigne F; Italiano A; Grellety T
Breast J; 2019 Sep; 25(5):971-973. PubMed ID: 31165561
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]